Idacio Purple Book BLA 761255

BLA number
761255
Proprietary names
Idacio
Proper names
adalimumab-aacf
Applicant
Fresenius Kabi USA, LLC
Center
CDER
First observed release
2022-12-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Idacioadalimumab-aacf351(k) Biosimilar40MG/0.8MLInjectionSubcutaneousAutoinjectorRxLicensed2022-12-13
002Idacioadalimumab-aacf351(k) Biosimilar40MG/0.8MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2022-12-13
003Idacioadalimumab-aacf351(k) Biosimilar40MG/0.8MLInjectionSubcutaneousSingle-Dose VialRxLicensed2024-01-05

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125057Humiraadalimumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-01-01N003Idacio351(k) BiosimilarRxFresenius Kabi USA, LLC
2022-12-01N001Idacio351(k) BiosimilarRxFresenius Kabi USA, LLC
2022-12-01N002Idacio351(k) BiosimilarRxFresenius Kabi USA, LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2024-01-01003Idacio351(k) BiosimilarRxLicensed2024-01-05
2022-12-01001Idacio351(k) BiosimilarRxLicensed2022-12-13
2022-12-01002Idacio351(k) BiosimilarRxLicensed2022-12-13